Chris Shibutani
Stock Analyst at Goldman Sachs
(3.16)
# 1,033
Out of 4,670 analysts
99
Total ratings
48.72%
Success rate
1.74%
Average return
Main Sectors:
Stocks Rated by Chris Shibutani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Upgrades: Buy | $90 → $137 | $113.13 | +21.10% | 7 | Nov 8, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $33 | $16.09 | +105.10% | 3 | Nov 7, 2024 | |
| UTHR United Therapeutics | Maintains: Neutral | $243 → $302 | $372.89 | -19.01% | 4 | Nov 1, 2024 | |
| ALKS Alkermes | Maintains: Buy | $32 → $30 | $28.78 | +4.24% | 6 | Oct 25, 2024 | |
| ERAS Erasca | Maintains: Buy | $3 → $3.5 | $2.70 | +29.63% | 6 | Oct 25, 2024 | |
| RPRX Royalty Pharma | Maintains: Buy | $50 → $51 | $26.43 | +92.96% | 3 | Aug 14, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $160 → $155 | $155.17 | -0.11% | 3 | Jul 19, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $3 → $4 | $5.27 | -24.10% | 8 | Jul 12, 2024 | |
| RVNC Revance Therapeutics | Maintains: Neutral | $9 → $8 | $3.73 | +114.48% | 5 | May 13, 2024 | |
| OGN Organon & Co. | Maintains: Neutral | $18 → $20 | $15.28 | +30.89% | 5 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $650 → $723 | $748.01 | -3.34% | 6 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $26 | $20.84 | +24.76% | 1 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $134 → $153 | $125.65 | +21.77% | 2 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $173 | $176.95 | -2.23% | 4 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.05 | - | 4 | Nov 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $4 → $1.25 | $0.77 | +62.63% | 3 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $81 → $69 | $58.87 | +17.21% | 5 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $13 | $19.15 | -32.11% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $23 | $56.75 | -59.47% | 3 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $1.85 | +2,602.70% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $52 | $44.98 | +15.61% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $47 → $60 | $25.65 | +133.92% | 2 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $18 | $18.80 | -4.26% | 4 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $3.92 | +333.67% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.81 | - | 1 | Jul 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.31 | - | 1 | Feb 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.00 | - | 4 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $20.21 | - | 3 | May 2, 2017 |
BioNTech SE
Nov 8, 2024
Upgrades: Buy
Price Target: $90 → $137
Current: $113.13
Upside: +21.10%
Syndax Pharmaceuticals
Nov 7, 2024
Maintains: Buy
Price Target: $30 → $33
Current: $16.09
Upside: +105.10%
United Therapeutics
Nov 1, 2024
Maintains: Neutral
Price Target: $243 → $302
Current: $372.89
Upside: -19.01%
Alkermes
Oct 25, 2024
Maintains: Buy
Price Target: $32 → $30
Current: $28.78
Upside: +4.24%
Erasca
Oct 25, 2024
Maintains: Buy
Price Target: $3 → $3.5
Current: $2.70
Upside: +29.63%
Royalty Pharma
Aug 14, 2024
Maintains: Buy
Price Target: $50 → $51
Current: $26.43
Upside: +92.96%
Johnson & Johnson
Jul 19, 2024
Maintains: Neutral
Price Target: $160 → $155
Current: $155.17
Upside: -0.11%
Amylyx Pharmaceuticals
Jul 12, 2024
Maintains: Neutral
Price Target: $3 → $4
Current: $5.27
Upside: -24.10%
Revance Therapeutics
May 13, 2024
Maintains: Neutral
Price Target: $9 → $8
Current: $3.73
Upside: +114.48%
Organon & Co.
May 6, 2024
Maintains: Neutral
Price Target: $18 → $20
Current: $15.28
Upside: +30.89%
Apr 11, 2024
Maintains: Neutral
Price Target: $650 → $723
Current: $748.01
Upside: -3.34%
Mar 1, 2024
Maintains: Neutral
Price Target: $29 → $26
Current: $20.84
Upside: +24.76%
Jan 25, 2024
Maintains: Buy
Price Target: $134 → $153
Current: $125.65
Upside: +21.77%
Dec 11, 2023
Upgrades: Buy
Price Target: $173
Current: $176.95
Upside: -2.23%
Nov 9, 2023
Upgrades: Outperform
Price Target: n/a
Current: $1.05
Upside: -
Nov 3, 2023
Maintains: Sell
Price Target: $4 → $1.25
Current: $0.77
Upside: +62.63%
Oct 30, 2023
Maintains: Buy
Price Target: $81 → $69
Current: $58.87
Upside: +17.21%
Mar 3, 2023
Maintains: Neutral
Price Target: $15 → $13
Current: $19.15
Upside: -32.11%
Mar 1, 2023
Maintains: Neutral
Price Target: $20 → $23
Current: $56.75
Upside: -59.47%
Dec 19, 2022
Initiates: Buy
Price Target: $50
Current: $1.85
Upside: +2,602.70%
Dec 16, 2022
Maintains: Buy
Price Target: $40 → $52
Current: $44.98
Upside: +15.61%
Dec 13, 2022
Upgrades: Buy
Price Target: $47 → $60
Current: $25.65
Upside: +133.92%
Nov 8, 2022
Maintains: Neutral
Price Target: $13 → $18
Current: $18.80
Upside: -4.26%
Sep 7, 2021
Initiates: Buy
Price Target: $17
Current: $3.92
Upside: +333.67%
Jul 14, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.81
Upside: -
Feb 10, 2020
Initiates: Outperform
Price Target: n/a
Current: $5.31
Upside: -
Jan 24, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $3.00
Upside: -
May 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $20.21
Upside: -